Anti-PD-L1 Antibody CDR Mutations for Tumor Inhibition
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current anti-PD-L1 therapies for cancer treatment have limitations in effectively targeting PD-L1, leading to incomplete immune evasion by cancer cells, necessitating the development of more potent and specific antibodies.
Innovation Solution
Development of novel anti-PD-L1 antibodies and their variants/mutants with specific amino acid sequences in the CDR regions, which enhance T-cell activation and cytokine secretion, and are designed to bind with high affinity to PD-L1, thereby blocking its immunosuppressive effects.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing anti-PD-L1 therapies are used, then cancer treatment is provided, but the effectiveness is limited due to incomplete blocking of PD-L1 immunosuppressive effects
Solution Approach 1:
The patent applies parameter changes by modifying the amino acid sequences in the CDR regions of the antibody variable domains. Specifically, the invention identifies and utilizes particular amino acid substitutions in CDR-L2 and CDR-H2 regions that enhance binding affinity to PD-L1, thereby improving therapeutic effectiveness without requiring complete structural redesign of the antibody molecule.
Solution Approach 2:
The invention applies local quality by focusing modifications specifically on the CDR regions (complementarity determining regions) of the antibody, particularly CDR-L2 and CDR-H2. These localized changes in amino acid sequence at the antigen-binding site enhance PD-L1 binding affinity while leaving the rest of the antibody structure relatively unchanged, thus improving effectiveness without proportionally increasing overall complexity.
2Force
If antibody affinity to PD-L1 is increased to block immunosuppressive effects, then T-cell activation is enhanced, but the manufacturing precision requirements increase
Solution Approach 1:
The patent defines specific amino acid parameter changes at key positions in the CDR regions. The invention specifies particular substitutions (e.g., CDR-L2: position 52; CDR-H2: position 57) that collectively enhance binding affinity. These parameter changes provide a clear, quantifiable approach to improving affinity while maintaining manufacturability through well-defined sequence requirements.
3Productivity
If novel anti-PD-L1 antibodies with enhanced T-cell activation are developed, then tumor growth inhibition is improved, but the development time and complexity increase
Solution Approach 1:
The patent applies preliminary action by identifying and characterizing the critical CDR region amino acid sequences that determine PD-L1 binding affinity and T-cell activation potential before full-scale development. The invention performs preliminary screening and selection of antibody variants with optimized CDR sequences, establishing a foundation for rapid development of high-efficacy therapeutics without requiring extensive de novo development.
Data Source
AI summary
Provided are anti-PD-L1 antibodies, variants, mutants, and antigen binding fragments thereof. Also provided are isolated nucleic acid molecules that encode the anti-PD-L1 antibodies, variants, mutants, or antigen binding fragments thereof, and related expression vectors, and host cells. Provided are methods of making anti-PD-L1 antibodies, variants, mutants, and antigen binding fragments thereof. Also provided are related pharmaceutical compositions and methods of their use to treat subjects. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present disclosure.